Benjamin Roy, MD
Psychiatry · Columbus, GANPI 1013021492
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Johnson & Johnson at 56.6% of the total. Reporting peaked in 2019 at $11,232 and has fallen 81.8% since, to $2,049 in 2025. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $78.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$13K
- Alkermes, Inc.$5K
- AbbVie$2K
- Neurocrine Biosciences, Inc.$633
- Teva Pharmaceuticals USA, Inc.$525
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$466
- plus $2K from 14 others
What the payments were for
- Consulting fees$7,94333%
- Speaking & faculty fees$9,04038%
- Travel & lodging$1,6207%
- Food & beverage$5,23422%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 21 | $13,482 |
| Alkermes, Inc. | 29 | $4,582 |
| AbbVie(2 entities) | 51 | $1,946 |
| Neurocrine Biosciences, Inc. | 29 | $633 |
| Teva Pharmaceuticals USA, Inc. | 33 | $525 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $466 |
| Indivior Inc. | 16 | $391 |
| Otsuka America Pharmaceutical, Inc. | 19 | $371 |
| Vanda Pharmaceuticals Inc. | 20 | $342 |
| E.r. Squibb & Sons, L.L.C. | 16 | $323 |
| Axsome Therapeutics, Inc. | 10 | $228 |
| Supernus Pharmaceuticals, Inc. | 12 | $176 |
| Lundbeck LLC | 4 | $78 |
| Sage Therapeutics, LLC | 1 | $63 |
| Sunovion Pharmaceuticals Inc. | 5 | $58 |
| Acadia Pharmaceuticals Inc | 1 | $53 |
| Avanir Pharmaceuticals, Inc. | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $42 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$16,533
- INVEGA SUSTENNA$13,259
- INVEGA TRINZA$12,579
- ARISTADA INITIO$4,133
- VRAYLAR$1,320
How this compares
$23,836 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 99 | $339,466 |
| Invega TrinzaPaliperidone Palmitate | 14 | $153,962 |
| CaplytaLumateperone Tosylate | 44 | $72,364 |
| VraylarCariprazine Hcl | 19 | $28,560 |
| RexultiBrexpiprazole | 17 | $26,050 |
| TrintellixVortioxetine Hydrobromide | 37 | $21,005 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $18,260 |
| Risperdal ConstaRisperidone Microspheres | 11 | $14,402 |
| Paliperidone ErPaliperidone | 47 | $8,709 |
| Divalproex Sodium ErDivalproex Sodium | 85 | $8,682 |
| Ziprasidone Hcl | 66 | $8,668 |
| Quetiapine Fumarate | 188 | $6,813 |
| Fluphenazine Hcl | 15 | $3,680 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 69 | $2,852 |
| Buspirone Hcl | 107 | $2,604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $13,482 | $507,830124 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $466 | $72,36444 claims |
| AbbVieVraylar | $1,946 | $28,56019 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $371 | $26,05017 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $42 | $21,00537 claims |
| Alkermes, Inc.Lybalvi | $4,582 | $18,26011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Columbus
- Kishor DesaiColumbus$11K
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
- Munjal ShroffSmyrna$316K
- David PurselleAtlanta$307K
- Jose CangianoAthens$244K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.